ORLANDO (EGMN) - Trastuzumab may be able to do for gastric cancer what it has already done for breast cancer: provide a significant survival advantage for patients whose tumors carry the HER2 receptor, investigators reported at the annual meeting of the American Society of Clinical Oncology.In a randomized phase III trial involving nearly 4,000 patients with advanced gastric cancers, 22.1% were found to have tumors that expressed the HER2 receptor at high levels. In these patients, introducing trastuzumab...